Dr Stephen Price
NIHR Clinician Scientist and Hon. Consultant Neurosurgeon
Dr Stephen Price is pleased to consider applications from prospective PhD students.
Preclinical and clinical imaging
Research on specific cancer types
My group uses advanced multimodal MR and PET imaging to understand the heterogeneity of gliomas (high and low grade) in individual patients. We know that gliomas are among the most heterogeneous tumours but still do not have a method of detecting this heterogeneity. Tissue markers cannot impact surgically based therapies. Imaging provides a non-invasive method of assessing tumour pathology.
My work focuses on two areas:
1. Intertumoural heterogeneity (i.e. differences between individuals). Especially heterogeneity of tumour invasion. Post-mortem studies show there is variation in tumour invasion with 20-25% of GBMs extend <1cm from the edge of the tumour mass, with another 20% extending >3 centimetres.
2. Intratumoural heterogeneity (i.e. differences within a tumour in an individual patient). Our work studies variation of response to chemotherapy/radiotherapy and drug uptake. We are developing [3-N-11C-methyl]-temozolomide a PET tracer to correlate response with drug uptake.
LA Mohsen, V Shi, R Jena, JH Gillard and SJ Price (2013). Diffusion tensor invasive phenotypes can predict progression-free survival in glioblastomas. British Journal of Neurosurgery. Feb 27. [Epub ahead of print].
SJ Price, HA Green, AF Dean, J Joseph, PJ Hutchinson, and JH Gillard (2011), “Correlation of MR Relative Cerebral Blood Volume Measurements with Cellular Density and Proliferation in High-Grade Gliomas: An Image-Guided Biopsy Study”, AJNR American Journal of Neuroradiology 32(3):501–506
Price SJ, Jena R, Burnet NG, Carpenter TA, Pickard JD, and Gillard JH (2007), “Predicting patterns of glioma recurrence using diffusion tensor imaging”, European Radiology 17(7):1675–1684
Norman Kirkby Web: http://portal.surrey.ac.uk/po...